Global In Vivo Electroporation Instrument Market, By Application (Biomedical research and Therapeutics), By End-user (Biotechnology and Pharmaceuticals company, Hospital, Academic Research and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI473121 | Publish Date: July 2023 | No. of Pages: 168

Global In Vivo Electroporation Instrument Market Overview

The Global Biometric Sensors Market accounted for US$ 128 Million 2020 and is estimated to be US$ 230.43 million by 2030 and is anticipated to register a CAGR of 6.1%.

Electroporation is a biotechnological procedure that involves passing an electric current through a live surface, such as a cell or a molecule. Pores emerge on the surface of the living structure in this fashion, allowing biological material to pass through readily. This method is commonly used to introduce viruses or plasmids into cells via pores in the cell membrane in the form of vectors or plasmids. Electroporation of the cell membrane occurs when cells are exposed to an electric field, and it has been researched and employed in a variety of applications in medicine and food biotechnology (e.g. electrochemotherapy, gene electrotransfer, extraction of biomolecules). Electroporation in vivo has become a popular method for creating nonviral gene treatments and nucleic acid vaccinations (NAV). The development of effective and nontoxic polynucleotide delivery systems is critical for the future of gene therapy. There are several methods for gene delivery, and in vivo gene transfer is currently divided into two categories: viral and non-viral delivery. In vivo electroporation (EP) is a technique for delivering bare plasmid DNA genes into living cells.

Global In Vivo Electroporation Instrument Market Drivers & Restraints

Increasing Demand for In-vivo Electroporation to Transfer Dyes, Ions, Nucleic Acids across Cell Membrane to Aid Market Growth

Technological advancements and R&D activities have played an imperative role in bringing about groundbreaking changes across the healthcare sector. The entry of new technologies has paved the way for cutting-edge medical devices that are increasingly being used to treat an array of medical diseases and conditions. Over the past couple of decades, major developments have occurred across the electroporation instruments market landscape, as market players continue to focus on improving the efficiency and performance of their products. Electroporation is an established physical technique that is primarily used to introduce polar molecules, including DNA into eukaryotic cells via the cell membrane.

As advancements in gene-editing techniques occur at a consistent pace, the prospects of the electroporation instruments market continue to stare at a bright future. Furthermore, with considerable growth in the research and development expenditure, electroporation is extensively being used to deliver chemotherapy drugs and gene electro transfer– factors that are expected to boo Furthermore, as electroporation penetrates 3D structures with high levels of efficiency, advanced gene editing techniques are likely to gain further traction in the upcoming decade.

Non-specific Transport and Other Damages to Hamper In-vivo electroporation Instruments Market

In-vivo electroporation methods have few disadvantages compared to other delivery systems

In some cases, non-specific transport of the material can result in an ion imbalance, which could lead to improper cell function and death. Irreversible electroporation could lead to loss of cell homeostasis, widely considered as unconventional mode for cell death.

In-vivo electroporation method causes complication and skin edema, as compared to other physical methods.

In other chemical methods, instruments are not required, which are highly preferred by some researchers. However, in some instances, electroporation effectiveness is widely influenced by other factors such as cell or tissue type and DNA formulation.

The method has some disadvantages, as there exists the potential for immunogenicity, random insertion and its mutagenesis in the genome, uncontrollable chronic expression of the gene, risk of systemic spread, and the fact that the quality control of viral particles for in vivo administration is a laborious and expensive protocol.3 In contrast, non-viral gene delivery is believed to be safer than viral delivery, and it has been shown that efficient and long-term expression could be expected.

Global In Vivo Electroporation Instrument Market Segmentations & Regional Insights

The global In Vivo Electroporation Instrument market is segmented based on application, end-user and region.

On the basis of Application, the global In vivo electroporation instrument market is segmented into Biomedical research and Therapeutics. Based on End-user, the target market is segmented into Biotechnology and Pharmaceuticals company, Hospital, Academic Research and Others.

Regional Insights:

On region the global In vivo electroporation instrument market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Presence of highly modern research facilities and diagnostic clinics, North America is expected to have the biggest market share for electroporation instruments, followed by Europe. Furthermore, the federal government's proper and advantageous reimbursement rules encourage people to use these electroporation tools. Electroporation was originally utilized in medicine to deliver anticancer medications to tumor nodules that were poorly permeable. Gene electrotransfer quickly gained popularity because to its inexpensive cost, ease of implementation, and safety.

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Application- Biomedical Research and Therapeutics

By End-user– Biotechnology and Pharmaceuticals company, Hospital, Academic Research and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global In vivo electroporation instrument market report based on application, and region.

Global In vivo Electroporation Instrument Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global In Vivo Electroporation Instrument Market Competitive Landscape & Key Players

The key players operating in the global In vivo electroporation instrument market includes Thermo Fisher Scientific, Inc., Merck, Lonza group, BEX, Celetrix LLC., Eppendorf AG, Harvard Bioscience Inc., Maxcyte Inc., Mirus Bio LLC, and Bio Rad laboratories. The companies are focusing on acquisitions and collaboration strategies to strengthen its market, which is expected to fuel the markets growth.

Global In Vivo Electroporation Instrument Market Company Profile

  • Thermo Fisher Scientific, Inc.*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck
  • Lonza group
  • BEX
  • Celetrix LLC.
  • Eppendorf AG
  • Harvard Bioscience Inc.
  • Maxcyte Inc.
  • Mirus Bio LLC
  • Bio Rad laboratories VIRCELL S.L.

 “*” marked represents similar segmentation in other categories in the respective section

FAQs

The global In vivo electroporation instrument market is segmented based on application, end-user and region.

As advancements in gene-editing techniques occur at a consistent pace, the prospects of the electroporation instruments market continue to stare at a bright future.

North America is expected to have the biggest market share for electroporation instruments, followed by Europe. This is mainly because of the presence of highly modern research facilities and diagnostic clinics in the region.

The companies are focusing on acquisitions and collaboration strategies to strengthen its market, which is expected to fuel the markets growth.3